Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001129928-20-000024
Filing Date
2020-05-08
Accepted
2020-05-08 09:00:08
Documents
6
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 2020 FIRST QUARTER 6-K q12020form6-k.htm 6-K 23207
2 2020 FIRST QUARTER INTERIM FINANCIAL STATEMENTS ex991-interimfsmar312020.htm EX-99.1 402994
3 2020 FIRST QUARTER MD&A ex992-q12020mda.htm EX-99.2 212142
4 Q1 2020 CERTIFICATION CEO ex993-q12020certificationx.htm EX-99.3 15635
5 Q1 2020 CERTIFICATION CFO ex994-q12020certificationx.htm EX-99.4 15416
6 oncolyticslogotaglinebluea06.jpg GRAPHIC 355294
  Complete submission text file 0001129928-20-000024.txt   1109878
Mailing Address 210 - 1167 KENSINGTON CRES NW CALGARY A0 T2N 1X7
Business Address 1167 KENSINGTON CRES NW SUITE 210 CALGARY ALBERTA CANADA T2N 1X7 ALBERTA CANADA A0 00000 4036707380
ONCOLYTICS BIOTECH INC (Filer) CIK: 0001129928 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-38512 | Film No.: 20858916
SIC: 2834 Pharmaceutical Preparations